Want to see TCMD full AI Analyst Report?
TCMD Stock Chart & Stats
$23.58
$0.28(1.02%)
At close: 4:00 PM EDT
$23.58
$0.28(1.02%)
Day’s Range― - ―
52-Week Range$14.46 - $37.77
Previous Close$27.76
Volume126.76K
Average Volume (3M)241.25K
Market Cap
$514.89M
Enterprise Value$631.20M
Total Cash (Recent Filing)$69.85M
Total Debt (Recent Filing)$14.36M
Price to Earnings (P/E)20.9
Beta0.71
Next Earnings
Nov 02, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.09
Shares Outstanding22,652,287
10 Day Avg. Volume197,355
30 Day Avg. Volume241,250
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)3.03
Price to Sales (P/S)2.01
P/FCF Ratio16.41
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda14.31
Forecast
1Y Price Target
$35.00Price Target Upside48.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.1
Revenue Forecast (FY)$362.38M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability GrowthStrong lymphedema demand is translating into both revenue growth and operating leverage. The combination of higher sales, gross-margin expansion, and faster EBITDA and net-income growth supports a more durable earnings base and funds continued investment.
Low Leverage And LiquidityA largely unlevered balance sheet gives Tactile financial flexibility to invest in products, pursue distribution opportunities, and withstand reimbursement or demand variability. Cash resources and minimal debt also reduce interest burden and refinancing pressure.
Clinical Evidence Supports AdoptionPositive randomized clinical evidence can strengthen physician confidence and support payer engagement for home-based therapy. Demonstrated comparability with therapist-guided care reinforces Flexitouch’s clinical value and may help sustain adoption across chronic swelling treatment.
Bears Say
Medicare Authorization FrictionThe new authorization process can create persistent friction between prescription and shipment, slowing revenue conversion and increasing administrative work. Lower Medicare order volumes also expose the business to reimbursement-policy execution risk within a meaningful payer channel.
Weaker Cash-Flow MomentumAlthough cash generation remains positive, the decline in operating and free cash flow reduces the pace at which earnings convert into internally funded investment. Cash flow trailing net income also indicates working-capital or timing pressure that could limit financial flexibility.
Indirect-Channel ConcentrationDependence on a small group of large DME accounts increases the risk that partner inventory decisions will produce uneven orders and revenue. This channel structure can make demand less predictable and complicate planning for the airway-clearance business.
Tactile Systems Technology News
TCMD FAQ
What was Tactile Systems Technology’s price range in the past 12 months?
Tactile Systems Technology lowest stock price was $14.46 and its highest was $37.77 in the past 12 months.
What is Tactile Systems Technology’s market cap?
Tactile Systems Technology’s market cap is $514.89M.
When is Tactile Systems Technology’s upcoming earnings report date?
Tactile Systems Technology’s upcoming earnings report date is Nov 02, 2026 which is in 13 days.
How were Tactile Systems Technology’s earnings last quarter?
Tactile Systems Technology released its earnings results on Aug 10, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.135 by $0.205.
Is Tactile Systems Technology overvalued?
According to Wall Street analysts Tactile Systems Technology’s price is currently Undervalued.
Does Tactile Systems Technology pay dividends?
Tactile Systems Technology does not currently pay dividends.
What is Tactile Systems Technology’s EPS estimate?
Tactile Systems Technology’s EPS estimate is 0.28.
How many shares outstanding does Tactile Systems Technology have?
Tactile Systems Technology has 22,652,287 shares outstanding.
What happened to Tactile Systems Technology’s price movement after its last earnings report?
Tactile Systems Technology reported an EPS of $0.34 in its last earnings report, beating expectations of $0.135. Following the earnings report the stock price went down -17.124%.
Which hedge fund is a major shareholder of Tactile Systems Technology?
Currently, no hedge funds are holding shares in TCMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tactile Systems Technology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (48.43% Upside)
$35.00 (48.43% Upside)
Blogger Sentiment
Bullish
TCMD Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 265.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $323.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.43%
12-Months-Change
Fundamentals
Return on Equity
11.49%
Trailing 12-Months
Asset Growth
2.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tactile Systems Technology
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
TCMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid overall momentum driven by a strong lymphedema business, meaningful margin and profitability expansion, supportive clinical evidence publication, and strategic product and distribution initiatives (LymphaTech, MyoSleeve, next‑gen AffloVest). Near-term headwinds are limited and identifiable—chiefly temporary DME inventory management affecting AffloVest, Medicare prior authorization timing effects, and planned expense and strategic cash deployment—while multiyear fundamentals and guidance were maintained/upgraded. Taken together, positives around revenue growth, margin expansion, durable AffloVest TTM growth, and clinical/regulatory progress outweigh the transitory challenges.View all TCMD earnings summariesTCMD Stock 12 Month Forecast
Average Price Target
$35.00
▲(48.43% Upside)
Technical Analysis
Ownership Overview
3.50% Insiders
20.46% Mutual Funds
1.70% Other Institutional Investors
52.75% Public Companies and
Individual Investors